Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin

January 15, 2026 | Comments Off on Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin

Cancer Research Communications 2025 December 10 [Link] Pınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, Kirstine Sandal Nørregaard, Henrik Gårdsvoll, Jingli Zhang, Henrik Jessen Jürgensen, Michaela Hansen Blomquist, Alba Martinez…

Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype

January 14, 2026 | Comments Off on Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype

Journal of Thoracic Oncology 2025 November 28 [Link] David T Severson, Samuel Freyaldenhoven, Benjamin Wadowski, Yin P Hung, Travis Hughes, Beow Y Yeap, William G Richards, Sanna Laaksonen, Lucian Chirieac,…

Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma

January 13, 2026 | Comments Off on Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma

Lung Cancer 2025 December [Link] Evgeniya Sharova, Paola Del Bianco, Loredana Urso, Micol Silic-Benussi, Daniela Scattolin, Donna M D’Agostino, Giulia Pasello, Vincenzo Ciminale Abstract Introduction: Pleural mesothelioma (PM) is an…

Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study

January 12, 2026 | Comments Off on Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study

The Lancet. Oncology 2025 December [Link] Li-Anne H Douma, Vincent van der Noort, Ferry Lalezari, Jeltje F de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus…

A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing

January 9, 2026 | Comments Off on A novel malignant mesothelioma organoids-T cell co-culture platform for personalized immunochemotherapy testing

Scientific Reports 2025 November 21 [Link] Yang Liu, Yang Yang, Songlin An, Hua Wan, Minghao Zhang, Ruihong Yin, Weiting Zhao, Li Huang, Yunshan Zhao, Chenggang Li Abstract Malignant mesothelioma (MM)…

Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases

January 8, 2026 | Comments Off on Hyperthermic Intrathoracic Chemotherapy and Photodynamic Therapy: A Single-Institution Experience for Malignant Pleural Diseases

Oncology 2025 November 20 [Link] Yu-An Zheng, Ke-Cheng Chen, Pei-Ming Huang, Mong-Wei Lin, Shuenn-Wen Kuo, Jang-Ming Lee Abstract Introduction: Hyperthermic intrathoracic chemotherapy (HITHOC) is an intraoperative treatment that involves the…

Unraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Management

January 7, 2026 | Comments Off on Unraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Management

Cureus 2025 October 15 [Link] Othmane Zouiten, Latifa Azarou, Hasnaa Hadiri, Hanane Rais, Rhizlane Belbaraka Abstract Peritoneal mesothelioma is a rare and aggressive tumor, and its management remains poorly standardized…

Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma

January 6, 2026 | Comments Off on Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma

Clinical and Experimental Medicine 2025 November 18 [Link] Jun Li, Hongye He, Yutao Zhang, Muhammad Salman Azhar, Yongxiang Wang Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive thoracic…

Positron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature

January 5, 2026 | Comments Off on Positron emission tomography/computed tomography in risk-factor-negative young female with malignant pleural mesothelioma: A case report and review of literature

World Journal of Clinical Cases 2025 November 16 [Link] Aikedan Aisikaer, Mo-Mo Sun, Jie Shen Abstract Background: Malignant pleural mesothelioma (MPM), a rare aggressive malignancy, is primarily caused by asbestos…

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

December 19, 2025 | Comments Off on Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology 2025 November 14 [Link] Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M H Hendriks, Jo…

Categories